▎WuXi AppTec Content Team Report

Public information shows that a number of China's innovative medical device companies announced new financing progress in February this year.。In terms of financing rounds,The majority are early-stage financings, with 80% of the total financing rounds occurring before Series B.. From the perspective of the research field,The products developed by these companies include2D/4D Intracardiac Echocardiography (ICE) and other interventional imaging-related products, the application of hydrogel myocardial repair technology in the field of heart failure treatment, biocompatible micro-electromechanical technology, wound management and infection control products, etc.This article will combine the company's official press release to share the basic information of 10 new companies for readers' reference only.

Note:This table was compiled by "MedView" based on publicly available information and is an incomplete statistic.Statistical Period:2024/2/1-2024/2/27。If there are any omissions, please feel free to add.

Rebeccatech Medical

R&D Field: MEMS RF Technology

February 1 News: Hangzhou Rebeccatech Medical Technology co.LTD (Rebecca Tech) announced the completion of a multi-million-dollar A++ round of financing. This round of financing was led byPowerHealth FundLeading investment,PwC LeadingFollow-up Investment. Hangzhou Rebeccatech Medical Technology co.LTD was founded in 2015, focusing onBiocompatible MEMS TechnologyThe development, and is committed to promoting its application in urology, hepatology,DermatologyClinical applications in fields such as... The company has developedOveractive Bladder (OAB) Micro Radiofrequency Treatment DeviceAlready approved in China, it is performed through a single-use catheter combined with micro-radiofrequency equipment.Radiofrequency Neurotomy of the Bladder Neck, thereby reducing nerve sensitivity. The product achieves a 74% improvement rate in treating OAB symptoms.

PVmed

Research and Development Field:Intelligent Precision Oncology Treatment Product

On February 2, PVmed announced the completion ofZhuji Xienoxing Vision Venture Investment PartnershipPVmed, established in 2017, has secured 90 million yuan in Series B strategic financing. The company is committed to advancing multidisciplinary integration for intelligent precision oncology treatment. PVmed has developed products such as an AI-based radiotherapy target contouring system, comprehensive intelligent radiotherapy solutions, and a universal AI technology platform for minimally invasive surgeries based on intelligent vision. This round of financing will accelerate...PVmedResearch, production, and registration of integrated hardware and software intelligent precision oncology treatment solutions.

HugeMed

R&D Field:Endoscope

On February 6, HugeMedAnnounced the completion of a new round of financing worth hundreds of millions of yuan, byQiming Venture CapitalExclusive Investment. HugeMed was founded in 2014, dedicated to providing endoscopic solutions for clinical surgery, anesthesia, emergency, respiratory, pediatrics, ambulances, operating rooms, outdoor emergency care, etc., striving to cover non-invasive diagnosis and treatment through visualization of all natural body cavities. The company's products includeReusable EndoscopeAndDisposable endoscopes, etc.，which has currently obtained certifications from regulatory authorities such as the EU CE, US FDA, and China NMPA, and is sold in over 100 countries and regions.

AccuPulse

R&D Field: Products in the field of cardiac electrophysiology

News on February 7,AccuPulseAnnounced the completion of nearly 200 million yuan in A+ round financing, byShengshi Investment Management's Shaoxing Binhai New Area Biomedical Industry Equity Investment FundAndShanghai Biopharmaceutical FundCo-led the investment.AccuPulse Medical Technology Co.Ltd was founded in 2020 and is committed to becoming aCardiac ElectrophysiologyAn innovative technology company in the field. The companyTaking atrial fibrillation ablation as the entry point,Independently developedPulsed Electric Field Ablation（PFA）TechnicalHost Pulse Ablation Instrument and Ablation Catheter,The results of the interim analysis have met the early success criteria set by the clinical protocol.AccuPulse has further developed3D Mapping and Navigation System, which will combine with the next-generation intracardiac echocardiography (ICE) function to achieve ultrasound magnetic triple positioning technology. It is reported that AccuPulsePlan to complete within this yearPFAClinical Follow-up of Patients Enrolled in Product Registration Clinical TrialsAndFDA Submission for 3D Mapping System.

AIQ Medical

R&D Field: Innovative Products in Orthopedic Digital Technology

On February 8, Aijiao Medical announced the completion of a multi-million yuan A round of financing. This round of financing was led byYuan Yi CapitalAndSuzhou Industrial Park Science and Technology Innovation FundCo-investment. AccuPulse Medical Technology Co., Ltd. was founded in 2015, focusing onInnovative Medical Device for Digital Treatment of Bone and Joint DiseasesResearch and production, and promote the digital transformation of joint surgery. The company has launchedIntraoperative Digital Joint Surgery Assistance Solution, which supports real-time intraoperative measurement and decision-making without relying on preoperative imaging planning. Currently, products such as the iJoin Medical total knee arthroplasty positioning system and the knee joint soft tissue tension measurement device have been approved, with several other products in the clinical registration stage.

For Wheat Medical

R&D Field:Wearable Digital Vital Signs Management Products

On February 10, Weimai Medical announced the completion of a multi-million yuan A round of financing, led byXiamen Guomao Industrial Fund Managed by Guoxing InvestmentExclusive Investment. Weimai Medical was founded in 2014, focusing on wearable digital vital signs management solutions. Based on multi-frequency time-division multiplexing wireless technology and edge-cloud collaboration technology based on edge computing,Three Major Technology Platforms for Ultra-High Precision Data Restoration and Reconstruction，For PVmedFormationDigital Temperature ManagementAndDigitalizationVital Signs ManagementTwo product lines of solutions. Among them, the company's non-invasive monitoring of "core body temperature" is expected to solve the technical problem of core body temperature monitoring during the perioperative period.

GuiLing Medical

R&D Field:Wound Management and Infection Control Products

On February 18, Guiling Medical announced the completionByBlue Bay Sci-Tech GroupExclusively InvestedTens of Millions of Yuan in A+ Round Financing。Homing Medical was founded in2017, committed to providingInfection and Non-Healing WoundsProviding a complete set of solutions from precise debridement to prognosis management. The company has developedBone Marrow Blood Aspiration and Circulation DeviceSECCS system is a Class III medical device,During the surgery, it only takes 7 minutes to quickly extract and enrich mesenchymal stem cells from bone marrow blood, preparing bioactive bone, which significantly enhances bone regeneration capability.Clinically suitable for patients with bone defects and nonunion. The company's developed products also includePrecision Debridement Water Jet Power System, for wound bed preparation / axillary odor treatment;High-Purity Fully Degradable Local Drug Sustained-Release Carrier, applicable for solving the pain points of postoperative infections in clinical settings.

Dekker Medical

R&D Field:Hydrogel Myocardial Repair Technology for Treating Heart Failure

On February 20, Deko Medical announced the completion of its first round of strategic financing. The amount of this round of financing is tens of millions of RMB, led byTasly CapitalExclusive Investment. Deko Medical was founded in 2017, incubated by Denovo Medical, and is committed to the research and development of innovative medical devices, promotingHydrogel Myocardial Repair TechnologyApplication in the Field of Heart Failure Treatment. Deke Medical currently ownsThe Core of Hydrogel Treatment for Heart FailureTechnology and completed exploratory research, its R&DThe XDROP Transcatheter Endocardial Hydrogel Injection System isInjecting and implanting hydrogel into the myocardial wall through minimally invasive means, thereby thickening the myocardial wall, providing mechanical support to the ventricular wall, and ultimately slowing or even reversing ventricular dilation to improve cardiac physiological function. It is reported that Tasly has also reached a strategic cooperation intention with Deko Medical. In the future, the two parties will carry out in-depth cooperation in multiple directions such as R&D, clinical trials, and investment within the field of heart failure.

Jiyuan Medical

R&D Field: Disposable Electronic Hysteroscope, etc.

On February 20, JiYuan Medical announced the completion of its second round of Series A financing worth tens of millions of yuan, following the first round of Series A financing in 2023. Established in 2017, JiYuan Medical focuses on the research, production, and sales of disposable gynecological endoscopes. Through independent innovation and optimized integration, the company has built a multi-product technology platform for disposable endoscopes and developed an integrated solution for disposable gynecological endoscopes that aligns with the 3A+ gynecological endoscope technical concept, featuring "five-in-one" functionality. The 3A+ concept refers to availability anytime, anywhere, by anyone, with no risk of cross-infection. The proceeds from this round of financing will primarily be used for the research and development, global registration, certification, and production of JiYuan Medical's disposable electronic hysteroscope and accompanying disposable surgical instruments.

CardioVation Tech

R&D Field: 2D/4DIntracardiac Ultrasound Imaging System

On February 26, CardioVast Tech announced that following the Pre-A round of financing worth tens of millions of RMB led by Luxin Venture Capital and co-invested by Zhuhai Beiqing River in June 2023, it completed another roundTens of Millions of RMB in Additional Financing, byFunds under Tongfang InvestmentCo-led by a well-known medical fund in the industry,Zhuhai Beiqing RiverAdditional Investment. At the same time, Heart寰 Technology announced that it has officially started7.5F 2D Intracardiac Echocardiography Imaging System (ICE)The registered clinical trial involves an ultrasound catheter model with dimensions smaller than currently marketed ICE products, which helps minimize complications from puncture injuries. Established in 2021, HeartSpace Technology is committed to developing globally innovative interventional imaging-related products such as 2D ICE and 4D ICE. Currently, the HeartSpace Technology team has also developed...4D ICE System, which integrates several cutting-edge ultrasound imaging technologies such as soft beam synthesis and arbitrary waveform transmission., which can effectively reduce the risk of cardiac interventional surgery and shorten the learning curve for operators.

In addition to the aforementioned companies, other medical device companies also announced the completion of financing in February this year. Due to space limitations, this article will not introduce them one by one. It is hoped that with the help of capital, these companies can accelerate.Innovative ProductsThe progress of research and development will benefit a large number of patients as soon as possible.